1. Home
  2. LEGN vs THG Comparison

LEGN vs THG Comparison

Compare LEGN & THG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • THG
  • Stock Information
  • Founded
  • LEGN 2014
  • THG 1852
  • Country
  • LEGN United States
  • THG United States
  • Employees
  • LEGN N/A
  • THG N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • THG Property-Casualty Insurers
  • Sector
  • LEGN Health Care
  • THG Finance
  • Exchange
  • LEGN Nasdaq
  • THG Nasdaq
  • Market Cap
  • LEGN 7.0B
  • THG 5.9B
  • IPO Year
  • LEGN 2020
  • THG 1995
  • Fundamental
  • Price
  • LEGN $39.70
  • THG $156.56
  • Analyst Decision
  • LEGN Strong Buy
  • THG Buy
  • Analyst Count
  • LEGN 12
  • THG 8
  • Target Price
  • LEGN $79.50
  • THG $175.25
  • AVG Volume (30 Days)
  • LEGN 976.3K
  • THG 252.5K
  • Earning Date
  • LEGN 03-10-2025
  • THG 02-04-2025
  • Dividend Yield
  • LEGN N/A
  • THG 2.30%
  • EPS Growth
  • LEGN N/A
  • THG 1093.97
  • EPS
  • LEGN N/A
  • THG 11.70
  • Revenue
  • LEGN $520,183,000.00
  • THG $6,237,400,000.00
  • Revenue This Year
  • LEGN $121.13
  • THG N/A
  • Revenue Next Year
  • LEGN $65.25
  • THG $5.79
  • P/E Ratio
  • LEGN N/A
  • THG $13.40
  • Revenue Growth
  • LEGN 122.96
  • THG 4.07
  • 52 Week Low
  • LEGN $30.17
  • THG $119.66
  • 52 Week High
  • LEGN $70.13
  • THG $166.98
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 64.82
  • THG 46.52
  • Support Level
  • LEGN $34.36
  • THG $159.13
  • Resistance Level
  • LEGN $36.39
  • THG $166.98
  • Average True Range (ATR)
  • LEGN 1.67
  • THG 3.27
  • MACD
  • LEGN 0.34
  • THG -0.40
  • Stochastic Oscillator
  • LEGN 94.68
  • THG 37.10

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About THG Hanover Insurance Group Inc

The Hanover Insurance Group Inc is a holding company whose primary business is offering property and casualty insurance products and services. The company markets itself through independent agents and brokers in the United States while conducting business internationally through a wholly owned subsidiary, Chaucer Holdings Limited, domiciled in the United Kingdom. The company conducts business operations through three operating segments: Commercial Lines, Personal Lines, and Other. The company operates an investment portfolio that is exposed to fixed-income securities.

Share on Social Networks: